Other single compounds

Version vom 7. Juli 2020, 10:19 Uhr

Thymosin

G-CSF
32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

hzVSF‐v13 Humanized virus suppressing factor‐variant 13 (hzVSF‐v13) is a monoclonal IgG4 against vimentin, which is expressed on the surface of virus‐infected cells.
32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

Omalizumab
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help? Anti-IgE mab, -IL6,-TNF,-IL1,-NFKB

'bradykinin antagonists Icatibant, Noscapine

32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32526773 2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Almitrine
32505756 2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
32505755 2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.

Nitric oxide
32526061 2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?
32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.
32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.

PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

H2S
32515982 2020. H2S as a potential defence against COVID-19?

Anti microbials
32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Azithromycin
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.
32511867 2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.
32510734 2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.

Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32454071 2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.

Doxycycline and other Tetracyclins
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
32533795 2020. Further aspects of doxycycline therapy in COVID-19.
32379302 2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Lauric acid nat. compd.

• call for trial

Nicotine nat. toxin

• france

32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

CGRP calcitonin gene related peptide antagonists
32386433 2020. Could CGRP Antagonists Be Helpful in the Fight Against COVID-19?

Various Leads

• 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
• paper in nature

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

BRD4 polycomb
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.

Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.

Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

Camostat mesilate serine proteinase inh
32347443 ä. Camostat mesilate therapy for COVID-19
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor? Nafamostat mesilate serine proteinase inh
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.

Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy

Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases

Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.
32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
32467020 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? .
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?

Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review

TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection
32292907 2020. Standing out from the crowd in treating COVID-19 the title has been idioted from Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.

TRPV4 target
32401673 2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.

Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1

Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?

Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets

Retinoids
32459003 2020. A role for retinoids in the treatment of COVID-19?

Isotretinoin
32406143 2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?

Fenretinide
32471278 2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.

Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
31931639 2020. Dapsone as treatment adjunct in ARDS

Apremilast
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.

Clozapine
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19

Dextrometorphan

• dextrometorphan (antitussive compd)

Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management

tPA

32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.

Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
32410266 2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.

Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors

Alisporivir

Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Bee venom
32360140 ä. Bee venom and SARS-CoV-2

Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19

Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

akt PKB
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?

Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.

Pannexin1 channels
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.

NAD+
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.

Erythropoietin
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
32479920 2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.
32534130 2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.

Celastrol
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?

1
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19

Ozone
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.

stimulating the Platelets

Thrombomodulin
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome

Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments

• paper

nAChR as target
32387130 ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function

Lipids
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.

32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

Resolvins
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential

beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?

Lithium
32435920 2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?
32534451 2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
32518634 2020. Lithium and coronaviral infections. A scoping review.
32408073 2020. Lithium for the 2019 novel coronavirus

Resveratrol
32412158 2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
32310688 2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.

Curcumin
32442323 2020. Curcumin as a potential treatment for COVID-19.
32430996 2020. Potential effects of curcumin in the treatment of COVID-19 infection.
32488956 2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?

Quercetin
32455629 2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.

Copper
32388476 2020. Is copper beneficial for COVID-19 patients?
32503814 2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.

Bismuth
32516203 2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.

Anti Neoplastic agents
32398164 2020. Drug repurposing against COVID-19: focus on anticancer agents.

5-Fluorouracil 5-FU
32438240 2020. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection

Gargling mouth rinses
32395245 2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.

PVP iodine
32520599 2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.

Bromhexin
32458206 2020.... bromhexine as add-on therapy?

mabs
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32514101 2020. First antibody against COVID-19 spike protein enters phase I.
32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.

tlr's
32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.

p38 mapk
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.

lactoferrin
32529963 2020. Can lactoferrin boost human immunity against COVID-19?

Famotidine
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.

Ursodeoxycholic acid
32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.

Diethylcarbamazine anti-filarial
32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?

Nitrofurazoxide

Parthenolide
32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.

Proteasome inh
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.

Lidocaine
32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.

Escin
32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. Methioninase
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.

Thalidomide
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.

Pentoxyfylline
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?

P2X7 purinoceptor
32441783 2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).

PARP inh
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?

P selectin block
32464083 2020. P-selectin blockade in COVID-19-related ARDS.

Lysosomes, Autophagy, Membranes
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?

microbiome 2x
32495940 2020. Probiotics and COVID-19: is there any link?

32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.